WO2015014903A3 - Diagnostic tools for alzheimer's disease - Google Patents

Diagnostic tools for alzheimer's disease Download PDF

Info

Publication number
WO2015014903A3
WO2015014903A3 PCT/EP2014/066414 EP2014066414W WO2015014903A3 WO 2015014903 A3 WO2015014903 A3 WO 2015014903A3 EP 2014066414 W EP2014066414 W EP 2014066414W WO 2015014903 A3 WO2015014903 A3 WO 2015014903A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
alzheimer
diagnostic tools
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/066414
Other languages
French (fr)
Other versions
WO2015014903A2 (en
Inventor
Daniel Cohen
Ilya Chumakov
Serguei Nabirotchkin
Mickael Guedj
Rodolphe HAJJ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharnext SA
Original Assignee
Pharnext SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext SA filed Critical Pharnext SA
Priority to US14/908,612 priority Critical patent/US20160195547A1/en
Priority to ES14744599T priority patent/ES2731678T3/en
Priority to EP14744599.3A priority patent/EP3028049B1/en
Publication of WO2015014903A2 publication Critical patent/WO2015014903A2/en
Publication of WO2015014903A3 publication Critical patent/WO2015014903A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Computational Biology (AREA)

Abstract

The present invention relates to methods of detecting Alzheimer's disease using novel biomarkers. The novel biomarkers can be measured in biological body fluids or easily available extracts of biopsies. The present invention also relates to methods for identification of the stage of the disease, assessing the responsiveness to the treatment and the efficacy of treatment in subjects having Alzheimer's disease.
PCT/EP2014/066414 2013-07-31 2014-07-30 Diagnostic tools for alzheimer's disease Ceased WO2015014903A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/908,612 US20160195547A1 (en) 2013-07-31 2014-07-30 Diagnostic tools for alzheimer's disease
ES14744599T ES2731678T3 (en) 2013-07-31 2014-07-30 Diagnostic tools for Alzheimer's disease
EP14744599.3A EP3028049B1 (en) 2013-07-31 2014-07-30 Diagnostic tools for alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13178711.1 2013-07-31
EP13178711 2013-07-31

Publications (2)

Publication Number Publication Date
WO2015014903A2 WO2015014903A2 (en) 2015-02-05
WO2015014903A3 true WO2015014903A3 (en) 2015-06-04

Family

ID=48906136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/066414 Ceased WO2015014903A2 (en) 2013-07-31 2014-07-30 Diagnostic tools for alzheimer's disease

Country Status (4)

Country Link
US (1) US20160195547A1 (en)
EP (1) EP3028049B1 (en)
ES (1) ES2731678T3 (en)
WO (1) WO2015014903A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3375172B1 (en) * 2016-02-23 2020-04-29 Google LLC Identifying user device status via rotating codes broadcast by a beacon device
EP3555615B9 (en) 2016-12-19 2025-03-19 Metabolon, Inc. Mass spectrometry assay method for detection and quantitation of kidney function metabolites
US11881311B1 (en) * 2017-02-17 2024-01-23 BioAge Labs, Inc. Survival prediction using metabolomic profiles
KR20250079925A (en) * 2018-09-26 2025-06-04 아지노모토 가부시키가이샤 Mild-cognitive-impairment evaluation method, calculation method, evaluation device, calculation device, evaluation program, calculation program, recording medium, evaluation system, and terminal device
AU2019320619B2 (en) 2018-10-30 2021-10-14 Kurume Research Park Co., Ltd. Disease risk assessment apparatus, disease risk assessment method, program, and food for dementia prevention
WO2020252206A1 (en) * 2019-06-12 2020-12-17 Huntington Medical Research Institutes Methods for evaluation and treatment of alzheimer's disease and applications thereof
CN110333310B (en) * 2019-08-16 2022-02-11 大连医科大学附属第一医院 Group of biomarkers for diagnosing AD in a subject or determining the risk of developing AD in a subject and uses thereof
WO2022270901A1 (en) * 2021-06-25 2022-12-29 장재원 Early diagnosis system utilizing standard deviation and autocorrelation of dynamic fluorescent or x-ray
CN118090930A (en) * 2022-11-25 2024-05-28 中国科学院深圳先进技术研究院 Alzheimer's disease markers based on blood metabolites and their applications
WO2024108603A1 (en) * 2022-11-25 2024-05-30 中国科学院深圳先进技术研究院 Fecal metabolite-based neurodegenerative disease marker, and use thereof
CN120161156A (en) * 2023-12-14 2025-06-17 中国科学院深圳先进技术研究院 A biomarker for Alzheimer's disease based on brain metabolites and its application
CN118914534A (en) * 2024-08-20 2024-11-08 陕西科技大学 Volatile biomarker for predicting AD development, screening method and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064784A1 (en) * 2005-11-30 2007-06-07 The University Of Maryland, Baltimore Inhibitors of kynurenine aminotransferase and uses therefor
EP2085082A1 (en) * 2008-01-29 2009-08-05 Nutromnia S.R.L. Treatment of cognitive decline
US20100124756A1 (en) * 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
WO2012168561A1 (en) * 2011-06-10 2012-12-13 Teknologian Tutkimuskeskus Vtt Method of diagnosing on increased risk of alzheimer's disease
WO2013059234A1 (en) * 2011-10-18 2013-04-25 Metabolon, Inc. Biomarkers for amyotrophic lateral sclerosis and methods using the same
WO2013070839A1 (en) * 2011-11-11 2013-05-16 Metabolon, Inc. Biomarkers for bladder cancer and methods using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260834A1 (en) * 2002-08-20 2008-10-23 Martin Burke Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
KR101529318B1 (en) * 2005-12-19 2015-06-16 파마인 코포레이션 A hydrophobic core carrier composition for delivering a therapeutic agent, a method for preparing the same, and a method for using the composition
WO2009048522A1 (en) * 2007-10-11 2009-04-16 Richard Fuisz Smokeless tobacco product

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064784A1 (en) * 2005-11-30 2007-06-07 The University Of Maryland, Baltimore Inhibitors of kynurenine aminotransferase and uses therefor
EP2085082A1 (en) * 2008-01-29 2009-08-05 Nutromnia S.R.L. Treatment of cognitive decline
US20100124756A1 (en) * 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
WO2012168561A1 (en) * 2011-06-10 2012-12-13 Teknologian Tutkimuskeskus Vtt Method of diagnosing on increased risk of alzheimer's disease
WO2013059234A1 (en) * 2011-10-18 2013-04-25 Metabolon, Inc. Biomarkers for amyotrophic lateral sclerosis and methods using the same
WO2013070839A1 (en) * 2011-11-11 2013-05-16 Metabolon, Inc. Biomarkers for bladder cancer and methods using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EUGENIA TRUSHINA ET AL: "Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer's Disease Using Metabolomics", PLOS ONE, vol. 8, no. 5, 20 May 2013 (2013-05-20), pages e63644, XP055176105, DOI: 10.1371/journal.pone.0063644 *
JAMES D. DOECKE: "Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease", ARCHIVES OF NEUROLOGY (AMERICAN MEDICAL ASSOCIATION), vol. 69, no. 10, 1 October 2012 (2012-10-01), Chicago IL USA, pages 1318, XP055094705, ISSN: 0003-9942, DOI: 10.1001/archneurol.2012.1282 *
MUTH A ET AL: "Simultaneous enantioselective analysis of chiral urinary metabolites in patients with Zellweger syndrome", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 792, no. 2, 25 July 2003 (2003-07-25), pages 269 - 277, XP004434982, ISSN: 1570-0232, DOI: 10.1016/S1570-0232(03)00285-X *

Also Published As

Publication number Publication date
US20160195547A1 (en) 2016-07-07
EP3028049A2 (en) 2016-06-08
ES2731678T3 (en) 2019-11-18
WO2015014903A2 (en) 2015-02-05
EP3028049B1 (en) 2019-03-20

Similar Documents

Publication Publication Date Title
WO2015014903A3 (en) Diagnostic tools for alzheimer's disease
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
WO2016040891A3 (en) In vitro compositions comprising human sample and amyloid targeting agent
WO2014107599A3 (en) Compositions and methods for detecting protease activity in biological systems
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
WO2013063155A3 (en) Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
WO2012054589A3 (en) Conduit-containing devices and methods for analyte processing and detection
EP4495267A3 (en) Breast cancer detection kit or device, and detection method
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
WO2015157407A8 (en) Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
BR112014031365A2 (en) methods of detecting disease or conditions
EA201390150A1 (en) METHODS OF IDENTIFYING SIGNATURES OF DISEASE OR PATHOLOGICAL CONDITIONS IN THE FLOWS OF THE ORGANISM
HK1200037A1 (en) Non-invasive methods of detecting target molecules
WO2011015602A3 (en) Lung cancer biomarkers
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
HK1206423A1 (en) Oligomeric a in the diagnosis, prognosis, and monitoring of alzheimer's disease
BR112015008621A2 (en) METHODS AND DIAGNOSTIC AND / OR PROGNOSTIC KIT IN VITRO NUCLEIC ACID MICRO-ASSEMBLY.
HUE045724T2 (en) GRPR antagonists for the detection, diagnosis and treatment of GRPR-positive cancer
WO2013153461A3 (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
EP3385717A3 (en) Methods of detecting prostate cancer
WO2017027391A3 (en) Genetic abnormalities in plasma cell dyscrasias
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
WO2016205828A3 (en) Role of citrullination in diagnosing diseases
WO2014052921A3 (en) Patient health record similarity measure
WO2012006056A3 (en) Ccr6 as a biomarker of alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14744599

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14908612

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014744599

Country of ref document: EP